56 related articles for article (PubMed ID: 18801827)
1. Inhibition of THC-induced effects on the central nervous system and heart rate by a novel CB1 receptor antagonist AVE1625.
Zuurman L; Roy C; Schoemaker RC; Amatsaleh A; Guimaeres L; Pinquier JL; Cohen AF; van Gerven JM
J Psychopharmacol; 2010 Mar; 24(3):363-71. PubMed ID: 18801827
[TBL] [Abstract][Full Text] [Related]
2. Effect of intrapulmonary tetrahydrocannabinol administration in humans.
Zuurman L; Roy C; Schoemaker RC; Hazekamp A; den Hartigh J; Bender JC; Verpoorte R; Pinquier JL; Cohen AF; van Gerven JM
J Psychopharmacol; 2008 Sep; 22(7):707-16. PubMed ID: 18515447
[TBL] [Abstract][Full Text] [Related]
3. Modelling of the concentration--effect relationship of THC on central nervous system parameters and heart rate -- insight into its mechanisms of action and a tool for clinical research and development of cannabinoids.
Strougo A; Zuurman L; Roy C; Pinquier JL; van Gerven JM; Cohen AF; Schoemaker RC
J Psychopharmacol; 2008 Sep; 22(7):717-26. PubMed ID: 18583433
[TBL] [Abstract][Full Text] [Related]
4. Central nervous system effects of haloperidol on THC in healthy male volunteers.
Liem-Moolenaar M; te Beek ET; de Kam ML; Franson KL; Kahn RS; Hijman R; Touw D; van Gerven JM
J Psychopharmacol; 2010 Nov; 24(11):1697-708. PubMed ID: 20142302
[TBL] [Abstract][Full Text] [Related]
5. CB1 receptor antagonist AVE1625 affects primarily metabolic parameters independently of reduced food intake in Wistar rats.
Herling AW; Gossel M; Haschke G; Stengelin S; Kuhlmann J; Müller G; Schmoll D; Kramer W
Am J Physiol Endocrinol Metab; 2007 Sep; 293(3):E826-32. PubMed ID: 17595216
[TBL] [Abstract][Full Text] [Related]
6. Cannabidiol potentiates pharmacological effects of Delta(9)-tetrahydrocannabinol via CB(1) receptor-dependent mechanism.
Hayakawa K; Mishima K; Hazekawa M; Sano K; Irie K; Orito K; Egawa T; Kitamura Y; Uchida N; Nishimura R; Egashira N; Iwasaki K; Fujiwara M
Brain Res; 2008 Jan; 1188():157-64. PubMed ID: 18021759
[TBL] [Abstract][Full Text] [Related]
7. AVE1625, a cannabinoid CB1 receptor antagonist, as a co-treatment with antipsychotics for schizophrenia: improvement in cognitive function and reduction of antipsychotic-side effects in rodents.
Black MD; Stevens RJ; Rogacki N; Featherstone RE; Senyah Y; Giardino O; Borowsky B; Stemmelin J; Cohen C; Pichat P; Arad M; Barak S; De Levie A; Weiner I; Griebel G; Varty GB
Psychopharmacology (Berl); 2011 May; 215(1):149-63. PubMed ID: 21181124
[TBL] [Abstract][Full Text] [Related]
8. Role of cannabinoid receptors in inhibiting macrophage costimulatory activity.
Chuchawankul S; Shima M; Buckley NE; Hartmann CB; McCoy KL
Int Immunopharmacol; 2004 Feb; 4(2):265-78. PubMed ID: 14996418
[TBL] [Abstract][Full Text] [Related]
9. Involvement of 5-hydroxytryptamine1A receptors in Delta9-tetrahydrocannabinol-induced catalepsy-like immobilization in mice.
Egashira N; Matsuda T; Koushi E; Mishima K; Iwasaki K; Shoyama Y; Fujiwara M
Eur J Pharmacol; 2006 Nov; 550(1-3):117-22. PubMed ID: 17022969
[TBL] [Abstract][Full Text] [Related]
10. Unheated Cannabis sativa extracts and its major compound THC-acid have potential immuno-modulating properties not mediated by CB1 and CB2 receptor coupled pathways.
Verhoeckx KC; Korthout HA; van Meeteren-Kreikamp AP; Ehlert KA; Wang M; van der Greef J; Rodenburg RJ; Witkamp RF
Int Immunopharmacol; 2006 Apr; 6(4):656-65. PubMed ID: 16504929
[TBL] [Abstract][Full Text] [Related]
11. Surinabant, a selective cannabinoid receptor type 1 antagonist, inhibits Δ9-tetrahydrocannabinol-induced central nervous system and heart rate effects in humans.
Klumpers LE; Roy C; Ferron G; Turpault S; Poitiers F; Pinquier JL; van Hasselt JG; Zuurman L; Erwich FA; van Gerven JM
Br J Clin Pharmacol; 2013 Jul; 76(1):65-77. PubMed ID: 23278647
[TBL] [Abstract][Full Text] [Related]
12. Influence of the anabolic-androgenic steroid nandrolone on cannabinoid dependence.
Célérier E; Ahdepil T; Wikander H; Berrendero F; Nyberg F; Maldonado R
Neuropharmacology; 2006 Jun; 50(7):788-806. PubMed ID: 16443242
[TBL] [Abstract][Full Text] [Related]
13. Pharmacodynamic and pharmacokinetic effects of the intravenously administered CB1 receptor agonist Org 28611 in healthy male volunteers.
Zuurman L; Passier PC; de Kam Ml; Kleijn HJ; Cohen AF; van Gerven JM
J Psychopharmacol; 2009 Aug; 23(6):633-44. PubMed ID: 18635703
[TBL] [Abstract][Full Text] [Related]
14. Behavioural sensitization after repeated exposure to Delta 9-tetrahydrocannabinol and cross-sensitization with morphine.
Cadoni C; Pisanu A; Solinas M; Acquas E; Di Chiara G
Psychopharmacology (Berl); 2001 Nov; 158(3):259-66. PubMed ID: 11713615
[TBL] [Abstract][Full Text] [Related]
15. Acute delta9-tetrahydrocannabinol exposure facilitates quinpirole-induced hyperlocomotion.
Gorriti MA; Ferrer B; del Arco I; Bermúdez-Silva FJ; de Diego Y; Fernandez-Espejo E; Navarro M; Rodríguez de Fonseca F
Pharmacol Biochem Behav; 2005 May; 81(1):71-7. PubMed ID: 15894066
[TBL] [Abstract][Full Text] [Related]
16. A study investigating the acute dose-response effects of 13 mg and 17 mg Delta 9- tetrahydrocannabinol on cognitive-motor skills, subjective and autonomic measures in regular users of marijuana.
Weinstein A; Brickner O; Lerman H; Greemland M; Bloch M; Lester H; Chisin R; Sarne Y; Mechoulam R; Bar-Hamburger R; Freedman N; Even-Sapir E
J Psychopharmacol; 2008 Jun; 22(4):441-51. PubMed ID: 18635724
[TBL] [Abstract][Full Text] [Related]
17. Profiling of energy metabolism in olanzapine-induced weight gain in rats and its prevention by the CB1-antagonist AVE1625.
Liebig M; Gossel M; Pratt J; Black M; Haschke G; Elvert R; Juretschke HP; Neumann-Haefelin C; Kramer W; Herling AW
Obesity (Silver Spring); 2010 Oct; 18(10):1952-8. PubMed ID: 20168311
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic/pharmaco-dynamic modelling and simulation of the effects of different cannabinoid receptor type 1 antagonists on Δ(9)-tetrahydrocannabinol challenge tests.
Guan Z; Klumpers LE; Oyetayo OO; Heuberger J; van Gerven JM; Stevens J
Br J Clin Pharmacol; 2016 Apr; 81(4):713-23. PubMed ID: 26617196
[TBL] [Abstract][Full Text] [Related]
19. Novel Δ(9) -tetrahydrocannabinol formulation Namisol® has beneficial pharmacokinetics and promising pharmacodynamic effects.
Klumpers LE; Beumer TL; van Hasselt JG; Lipplaa A; Karger LB; Kleinloog HD; Freijer JI; de Kam ML; van Gerven JM
Br J Clin Pharmacol; 2012 Jul; 74(1):42-53. PubMed ID: 22680341
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and central nervous system effects of the novel dopamine D2 receptor antagonist JNJ-37822681.
te Beek ET; Moerland M; de Boer P; van Nueten L; de Kam ML; Burggraaf J; Cohen AF; van Gerven JM
J Psychopharmacol; 2012 Aug; 26(8):1119-27. PubMed ID: 21890591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
